FDA BioMarin Panel Highlights Differentiation for PTC Therapeutics (PTCT) - Oppenheimer

Tuesday's advisory panel for BMRN's exon-51 focused DMD candidate, Kyndrisa, highlighted key merits and differentiation of PTC Therapeutics (NASDAQ: PTCT) Translarna data set, according to Oppenheimer analyst Christopher Marai. The outlook seems positive for PTCT since the panel focus on safety differentiates Translarna's risk/benefit, PTCT has produced robust dystrophin-data and the FDA has OK'ed pooled analysis.

Marai does not believe dystrophin will be a sticking point for PTCT's Translarna panel. Furthermore, he anticipates PTCT will learn from BMRN's panel and augment discussion of relevance of subsets such as 300-400m with respect to the 6MWT endpoint.

PTCT has already justified its data to EU regulators, garnering conditional approval and he believes this process has strengthened PTCT's arguments supporting a positive risk/ benefit that will augment NDA filing.

No change to Outperform rating and $135 PT.

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $31.75 yesterday.

You May Also Be Interested In

• Jefferies Downgrades ULTA Salon (ULTA) to Hold, 'Competition Intensifying & Prestige Refresh Needed'
• BMO Capital on Netflix (NFLX): 'Thesis Intact'
• Comerica (CMA) PT Raised to $57 at DA Davidson